These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31729149)

  • 1. Cancer immunotherapy trial design with delayed treatment effect.
    Wu J; Wei J
    Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J; Wu J
    Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J; Li Y; Zhu L
    J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
    Ding X; Wu J
    Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S; Chu C; Rong A
    Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
    Li B; Su L; Gao J; Jiang L; Yan F
    Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z; Zhang Q; Xue A; Whitmore J
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J; Wei J
    Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
    Kaneko Y; Morita S
    J Biopharm Stat; 2024 Aug; 34(5):626-645. PubMed ID: 37585719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C; Liu S; Rong A
    Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing therapeutic cancer vaccine trials with delayed treatment effect.
    Xu Z; Zhen B; Park Y; Zhu B
    Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial design with growth modulation index as the primary endpoint.
    Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
    Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy trial design with long-term survivors.
    Ding X; Wu J
    Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
    Shan G
    J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group sequential multi-arm multi-stage survival trial design with treatment selection.
    Wu J; Li Y
    J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage phase II survival trial design.
    Wu J; Chen L; Wei J; Weiss H; Chauhan A
    Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and analysis of clinical trials in the presence of delayed treatment effect.
    Sit T; Liu M; Shnaidman M; Ying Z
    Stat Med; 2016 May; 35(11):1774-9. PubMed ID: 26833957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
    Ye T; Yu M
    Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.